Mohammad Haskali gained his Bachelor’s degree in analytical chemistry in 2008 from Victoria University (Australia). In 2014, Mohammad has submitted his PhD thesis from his research at the University of Melbourne in collaboration with the Peter MacCallum Cancer Centre. In his graduate studies, Mohammad synthesized novel peptide and improved their radiolabelling procedures. Furthermore, he succeeded in automating his procedures with either the TRACERlab FXFN module or the newly developed iPHASE Flexlab dual reactor. From January 2013 to October 2014, Mohammad worked at Cyclotek Pty. Ltd., Australia’s leading production facility for 18F-labeled radiopharmaceuticals. His major role in the company was in GMP validation of new 18F-labeled investigational medicinal products. His current role in the PET Radiopharmaceutical Sciences Section is to perform regular productions of 18F- and 11C-labeled radiotracers for clinical studies, develop processes and documents in support of Investigational New Drug applications, and also to develop fluorine-18 and carbon-11 radiochemistry.